- Home
- ORCL vs NVO Comparison
ORCL vs NVO Comparison
Compare ORCL & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORCL
- NVO
- Stock Information
- Founded
- ORCL 1977
- NVO 1923
- Country
- ORCL United States
- NVO Denmark
- Employees
- ORCL N/A
- NVO N/A
- Industry
- ORCL Computer Software: Prepackaged Software
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORCL Technology
- NVO Health Care
- Exchange
- ORCL Nasdaq
- NVO Nasdaq
- Market Cap
- ORCL 480.2B
- NVO 530.0B
- IPO Year
- ORCL 1986
- NVO N/A
- Fundamental
- Price
- ORCL $160.95
- NVO $78.71
- Analyst Decision
- ORCL Buy
- NVO Strong Buy
- Analyst Count
- ORCL 27
- NVO 6
- Target Price
- ORCL $185.08
- NVO $134.00
- AVG Volume (30 Days)
- ORCL 7.6M
- NVO 10.6M
- Earning Date
- ORCL 03-10-2025
- NVO 02-05-2025
- Dividend Yield
- ORCL 0.99%
- NVO 1.83%
- EPS Growth
- ORCL 13.17
- NVO 26.84
- EPS
- ORCL 4.09
- NVO 3.17
- Revenue
- ORCL $54,933,000,000.00
- NVO $40,469,178,712.00
- Revenue This Year
- ORCL $11.14
- NVO $24.51
- Revenue Next Year
- ORCL $12.58
- NVO $20.71
- P/E Ratio
- ORCL $39.36
- NVO $24.09
- Revenue Growth
- ORCL 6.40
- NVO 26.15
- 52 Week Low
- ORCL $106.51
- NVO $78.17
- 52 Week High
- ORCL $198.31
- NVO $148.15
- Technical
- Relative Strength Index (RSI)
- ORCL 40.22
- NVO 27.40
- Support Level
- ORCL $152.42
- NVO $80.05
- Resistance Level
- ORCL $168.05
- NVO $83.99
- Average True Range (ATR)
- ORCL 3.02
- NVO 1.63
- MACD
- ORCL -0.06
- NVO -0.05
- Stochastic Oscillator
- ORCL 45.56
- NVO 5.09
About ORCL Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has more than 400,000 customers in 175 countries.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.